Adaptimmune Therapeutics PLC reports results for the quarter ended in June - Earnings Summary

Adaptimmune Therapeutics

09/08/2021 21:34

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
June. The mean expectation of seven analysts for the quarter was
for a loss of 24 cents per share.
* Revenue rose 516.5% to $3.10 million from a year ago; 
analysts expected $1.36 million. 
* Adaptimmune Therapeutics PLC's reported EPS for the quarter
was a loss of 24 cents​.
* The mean earnings estimate of analysts had risen by about 0.5%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Adaptimmune Therapeutics PLC shares had fallen by 18.1% this
quarter and lost 35.3% so far this year.
* The company reported a quarterly loss of $39.07 million.
* Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $9.00 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 
This summary was machine generated August 9 at 08:34 p.m.  ​All
figures in US dollars unless otherwise stated